ClinicalTrials.gg
TerminatedNCT05470387INTEGRITYUpdated Jun 13, 2024Results posted

A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection

A Phase 3 interventional study of LB1148 and Placebo in Ileus and Gastro-Intestinal Disorder, sponsored by Palisade Bio. Terminated at 23 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-06-13.

Sponsored by Palisade Bio · Phase 3, Interventional, and Treatment

Why this study was terminated
Company decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Ileus with a site in United States — 4 open to participants now, 4 under way, 1 of them phase 3. Ileus · United States.

Enrollment
45th of 53
23 · median 80
Started
2022
with 3 others
Phase 3
11 of 59
none open now
Registered
54th of 59
by date
Lead sponsor
2 of 59
Palisade Bio

Among the 59 studies in Ileus with a site in United States, this one is the 45th largest by enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2022, is one of 11 in phase 3, and was the 54th registered.

Ileus

167 studies on the registry are indexed under Ileus; 23 are open to participants now.

Browse Ileus studies →

Open to participants now

4 of the 59 studies in Ileus with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Ileus studies recruiting now, 12 (63%) set no upper age limit and 4 (21%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Ileus with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of LB1148 in subjects undergoing planned bowel resection.

Read the detailed description

This will be a multicenter, randomized, double-blind, placebo-controlled, study to evaluate the safety and efficacy of LB1148 in return to bowel function for subjects undergoing planned bowel resection.

03

Conditions studied

  • Ileus
  • Gastro-Intestinal Disorder

Keywords

  • post operative ileus
  • return of bowel function
  • return of gastrointestinal function
  • enterotomy
  • colon surgery
  • colorectal surgery
  • intestinal surgery
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects will be eligible for participation in the study only if they meet ALL of the following inclusion criteria:

  1. Adults age 18 to 80 years, inclusive.
  2. Scheduled to undergo a planned (non-emergent) bowel resection via minimally invasive technique or laparotomy. This includes any subject in which a resection of the small intestine, colon, or rectum is performed for any elective indication.
  3. Willing to perform and comply with all study procedures including, being hospitalized until achieving GI-2 and responding to telephone follow-up visits as scheduled.
  4. Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

Subjects will not be eligible for participation in the study if they meet ANY of the following exclusion criteria:

  1. History of total colectomy.
  2. Has a preexisting ostomy.
  3. History of radiation enteritis.
  4. Estimated (eGFR) \< 30 mL/min/1.73 m2.
  5. History of seizure disorder.
  6. History of myeloproliferative disorders.
  7. (ASA) Class IV or V.
  8. Inability to take IP orally or consume solid food.
  9. Planned treatment with alvimopan (Entereg®) during hospitalization period
  10. Chronic opioid usage, defined by the American Pain Society as daily or near-daily use of opioids for at least 90 days.
  11. Men and women of child bearing potential () who are unwilling to practice a highly effective method of that may include, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with vasectomized partner, vasectomy, hysterectomy, bilateral tubal ligation, licensed hormonal methods (but not combination hormonal methods), intrauterine device, or use of spermicide combined with a barrier method (e.g., condom, diaphragm) for 28 days before Day 1 and through Day 30.
  12. Women who will not agree to stop combined hormonal contraceptive and or combined hormonal replacement therapy (including combined hormonal pill, patch or vaginal ring) during the 7 day period prior to Surgery (Study Day 2) through the 7 day period following surgery (Study Days 3 through 9).
  13. Has or potential risk factors to taking TXA. These include subjects with:

    • Known sensitivity to TXA
    • Recent craniotomy (past 30 days)
    • Active cerebrovascular bleed
    • Active thromboembolic disease (such as deep vein thrombosis, pulmonary embolism, cerebral thrombosis, ischemic stroke, or acute coronary syndrome)
    • Acute promyelocytic leukemia taking all-trans retinoic acid for remission induction
  14. Receipt of any drug within 28 days or 5 half-lives prior to Day 1.
  15. Any other condition that, in the opinion of the Investigator would make the subject unsuitable for the study or unable to comply with the study requirements.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    LB1148

    Drug: LB1148

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugLB1148

    Drug pages: Tranexamic Acid · Protease Inhibitor Formulation LB1148

    A total of 700 mL of drug product will be administered orally as a split dose before surgery.

    Also known as: Active

  • DrugPlacebo

    A total of 700 mL of placebo will be administered orally as a split dose before surgery.

06

What researchers measure

Primary outcomes

  1. Time to Return of Gastrointestinal Function

    The later of the times in hours from placement of the last skin staple or suture to the time of toleration of solid food (defined as the time a subject finished a meal that required chewing and experienced no significant nausea/vomiting for 4 hours after the solid meal) and the first bowel movement, up to 14 days post-surgery

    Time frame: From surgical procedure up to 14 days in hospital

Secondary outcomes

  1. Time to First Bowel Movement

    Time in hours from placement of the last skin staple or suture to the time of first bowel movement

    Time frame: From surgical procedure up to 14 days in hospital

  2. Time Subject is Ready for Discharge

    Time subject is ready for discharge, defined as the time from the end of surgery to the time the subject is ready for hospital discharge solely based on the recovery of GI function, as determined by the surgeon

    Time frame: From surgical procedure up to 14 days in hospital

  3. Time Discharge Order Written

    Time discharge order written, defined as the time from the end of surgery to the time that the hospital discharge order is written

    Time frame: From surgical procedure up to 14 days in hospital

  4. Time of Actual Discharge

    Time of actual discharge, defined as the time from the end of surgery to the time the subject is actually discharged from the hospital

    Time frame: From surgical procedure up to 14 days in hospital

07

Results

Posted Jun 13, 2024

Participant flow

Participant flow — Overall Study
MilestoneLB1148Placebo
Started1310
Completed137
Not completed03
Withdrew: Protocol violation03

Outcome measures

PrimaryTime to Return of Gastrointestinal Function

The later of the times in hours from placement of the last skin staple or suture to the time of toleration of solid food (defined as the time a subject finished a meal that required chewing and experienced no significant nausea/vomiting for 4 hours after the solid meal) and the first bowel movement, up to 14 days post-surgery

Time frame:
From surgical procedure up to 14 days in hospital
Reported as:
Mean · hours
Time to Return of Gastrointestinal Function
hoursLB1148Placebo
Time to Return of Gastrointestinal Function81.7 ± 44.6790.57 ± 76.25
SecondaryTime to First Bowel Movement

Time in hours from placement of the last skin staple or suture to the time of first bowel movement

Time frame:
From surgical procedure up to 14 days in hospital
Reported as:
Mean · hours
Time to First Bowel Movement
hoursLB1148Placebo
Time to First Bowel Movement51.54 ± 31.0846.67 ± 24.66
SecondaryTime Subject is Ready for Discharge

Time subject is ready for discharge, defined as the time from the end of surgery to the time the subject is ready for hospital discharge solely based on the recovery of GI function, as determined by the surgeon

Time frame:
From surgical procedure up to 14 days in hospital
Reported as:
Mean · hours
Time Subject is Ready for Discharge
hoursLB1148Placebo
Time Subject is Ready for Discharge154.48 ± 102.09113.11 ± 74.75
SecondaryTime Discharge Order Written

Time discharge order written, defined as the time from the end of surgery to the time that the hospital discharge order is written

Time frame:
From surgical procedure up to 14 days in hospital
Reported as:
Mean · hours
Time Discharge Order Written
hoursLB1148Placebo
Time Discharge Order Written155.62 ± 100.63113.11 ± 74.75
SecondaryTime of Actual Discharge

Time of actual discharge, defined as the time from the end of surgery to the time the subject is actually discharged from the hospital

Time frame:
From surgical procedure up to 14 days in hospital
Reported as:
Mean · hours
Time of Actual Discharge
hoursLB1148Placebo
Time of Actual Discharge159.01 ± 100.33116.81 ± 75.30

Adverse events

Collected over All AEs were collected for all subjects during their participation from Study Day 1 through Hospital Discharge or Day 16, whichever is earlier.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LB11480/13 (0%)7/13 (53.8%)13/13 (100%)
Placebo0/10 (0%)4/10 (40%)7/10 (70%)
Most frequent serious events
Most frequent serious events
EventLB1148Placebo
Postoperative IleusInjury, poisoning and procedural complications3/131/10
Anastomatic leakInjury, poisoning and procedural complications0/131/10
SepsisInjury, poisoning and procedural complications0/131/10
Respiratory AcidosisRespiratory, thoracic and mediastinal disorders0/131/10
Abdominal AbscessInjury, poisoning and procedural complications1/130/10
Gastrointestinal stoma necrosisInjury, poisoning and procedural complications1/130/10
Pelvic AbscessInjury, poisoning and procedural complications1/130/10
PneumonitisRespiratory, thoracic and mediastinal disorders1/130/10
Most frequent other events
Showing 10 of 32
Most frequent other events
EventLB1148Placebo
BradycardiaCardiac disorders2/134/10
Procedural HypotensionInjury, poisoning and procedural complications5/134/10
TachycardiaCardiac disorders4/132/10
AnaemiaBlood and lymphatic system disorders2/132/10
Procedural hypertensionInjury, poisoning and procedural complications2/132/10
HypertensionVascular disorders1/132/10
Postoperative ileusInjury, poisoning and procedural complications2/130/10
HyperglycaemiaMetabolism and nutrition disorders2/130/10
HypocalcaemiaMetabolism and nutrition disorders2/130/10
HypophosphataemiaMetabolism and nutrition disorders2/130/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)LB1148PlaceboTotal
<=18 years000
Between 18 and 65 years12719
>=65 years134
Age, Continuous
Age, Continuous(years)LB1148PlaceboTotal
Mean45.2 ± 12.5954.0 ± 17.4749.0 ± 15.21
Sex: Female, Male
Sex: Female, Male(Participants)LB1148PlaceboTotal
Female459
Male9514
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LB1148PlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American303
White101020
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)LB1148PlaceboTotal
United States131023
08

Study locations

23 sites
  • Site 315
    Mobile, Alabama 36617, United States
  • Site 354
    La Jolla, California 92037, United States
  • Site 329
    Orange, California 92868, United States
  • Site 350
    San Diego, California 92123, United States
  • Site 312
    Torrance, California 90502, United States
  • Site 359
    Bridgeport, Connecticut 06610, United States
  • Site 351
    Clearwater, Florida 33756, United States
  • Site 358
    Jacksonville, Florida 32224, United States
  • Site 331
    Miami, Florida 33136, United States
  • Site 357
    Iowa City, Iowa 52242, United States
  • Site 321
    Baltimore, Maryland 21237, United States
  • Site 324
    Burlington, Massachusetts 01805, United States
  • Site 355
    Grand Rapids, Michigan 49503, United States
  • Site 325
    Rochester, Minnesota 55905, United States
  • Site 352
    Saint Louis, Missouri 63110, United States
  • Site 317
    New York, New York 10029, United States
  • Site 356
    New York, New York 10032, United States
  • Site 318
    Chapel Hill, North Carolina 27599, United States
  • Site 313
    Columbus, Ohio 43210, United States
  • Site 353
    Providence, Rhode Island 02906, United States
  • Site 320
    Dallas, Texas 75390, United States
  • Site 319
    Houston, Texas 77030, United States
  • Site 326
    Salt Lake City, Utah 84132, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Mar 2023, 8 months.

Results were first posted in Jun 2024, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2022
First posted
Jul 22, 2022
StartActual
Jun 28, 2022
Primary completionActual
Mar 6, 2023
CompletionActual
Aug 11, 2023
Results first posted
Jun 13, 2024
Last update
Jun 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05470387
Lead sponsor
Palisade Bio
Responsible party
Sponsor
First posted
Jul 22, 2022
Start date
Jun 28, 2022
Primary completion
Mar 6, 2023
Completion
Aug 11, 2023
Results posted
Jun 13, 2024
Last update
Jun 13, 2024

Study contacts

Mitch Jones, MD
study director · CMO

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tranexamic Acid · Protease Inhibitor Formulation LB1148

Start the discussion